

References

I-207

1. Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. *J Hemat Oncol*.2018;11(61):1-5.
2. Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34/CD123 cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. *Haematologica*.2018;103(8):1288-1297.
3. Elzonris™ (tagraxofusp-erzs) injection, for intravenous use [package insert]. Stemline Therapeutics, Inc. New York, NY. Revised 07/2023.
4. Leukemia & Lymphoma Society. Blastic Plasmacytoid Dendritic Cell Neoplasm. Available at: <https://www.lls.org/leukemia/blastic-plasmacytoid-dendritic-cell-neoplasm>. Accessed. April 26, 2021
5. Micromedex DrugDex Compendium®. 2024. Tagraxofusp-erzs.
6. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Tagraxofusp-erzs.
7. Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological Malignancies. *Cancers*.2019;11(9):1358-1388.
8. Pemmaraju N, Lane A, Sweet K, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. *NEJM*.2019;380:1628-1637.
9. National Comprehensive Cancer Network (NCCN). Tagraxofusp-erzs. NCCN Drugs and Biologics Compendium®. 2024.

10. Tagraxofusp-erzs In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 09/21/2020.